HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Paclitaxel in the treatment of retinal tumors of LH beta-Tag murine transgenic model of retinoblastoma.

AbstractPURPOSE:
The purpose of this study was to investigate tumor control efficacy of paclitaxel in the treatment of retinal tumors harbored by the LH beta-Tag murine transgenic model of retinoblastoma.
METHODS:
LH beta-Tag-positive mice (n = 5) 10 weeks of age received two 20-microL subconjunctival injections delivered with a 72-hour interval to right eyes only. Paclitaxel was dissolved in 100% dimethyl sulfoxide (DMSO) and delivered at doses of 0.5 mg, 0.25 mg, 0.125 mg, 0.0625 mg, 0.0313 mg, and 0.0152 mg in a 20-microL volume. Control mice received two subconjunctival injections of DMSO or of saline solution to right eyes only or they remained untreated. Eyes were analyzed at 16 weeks of age for residual tumor burden, which was measured by gauging the cross-sectional area of largest tumor focus.
RESULTS:
Linear regression analysis of tumor burden demonstrates a statistically significant (P < 0.001) dose-response relationship between paclitaxel concentration and tumor size. Transient ocular toxicities were observed after treatment, but most had subsided at the time of analysis, 6 weeks after injection. After histologic assessment, the 0.25-mg paclitaxel dose had effectively reduced tumor burden and was associated with minimal toxicity, including mild conjunctival chemosis and fibrosis, corneal epitheliopathy, and corneal edema.
CONCLUSIONS:
Subconjunctival delivery of paclitaxel effectively inhibits intraocular tumor burden in the LH beta-Tag model of retinoblastoma. This treatment modality may represent a novel strategy for the clinical management of retinoblastoma.
AuthorsFernando Suárez, Maria-Elena Jockovich, Eleut Hernandez, William Feuer, Jean-Marie Parel, Timothy G Murray
JournalInvestigative ophthalmology & visual science (Invest Ophthalmol Vis Sci) Vol. 48 Issue 8 Pg. 3437-40 (Aug 2007) ISSN: 0146-0404 [Print] United States
PMID17652710 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents, Phytogenic
  • Luteinizing Hormone, beta Subunit
  • Paclitaxel
Topics
  • Animals
  • Antineoplastic Agents, Phytogenic (pharmacology, toxicity)
  • Conjunctiva
  • Disease Models, Animal
  • Injections, Intralesional
  • Linear Models
  • Luteinizing Hormone, beta Subunit (genetics)
  • Mice
  • Mice, Transgenic
  • Paclitaxel (pharmacology, toxicity)
  • Retinal Neoplasms (drug therapy, pathology)
  • Retinoblastoma (drug therapy, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: